Correlation between patient recall of bone densitometry results and subsequent treatment adherence

Treatment of osteoporosis is often inadequate. One reason can be insufficient patient education following diagnostic bone densitometry (DXA). Therefore, we studied how patients are informed and treated following their first DXA. Individuals who had DXA at a rural hospital in Wisconsin were surveyed with a questionnaire regarding their post-test education and prescribed treatment. Their DXA results and the specialty of their clinician were also recorded. Eighty percent of the 1,014 participants were informed of their results. Of the 341 participants who had normal bone mineral density (BMD), 63% reported correct results, while only 31% of the 309 who had osteopenia and 50% of the 364 who had osteoporosis reported correct results. Accuracy in reporting was not affected by the patients’ age or the specialty of their clinicians. Following DXA, 339 patients (33%) were started on medications; 86% of those remained on some prescribed therapy for osteoporosis, but 140 (41%) did not continue the initial medication. Reasons for discontinuation included side effects (48%) and cost (26%). Patients with low BMD who correctly reported their results were more likely to have received a medication and to continue to take it ( p <0.0001). Calcium supplements were recommended to 65% of those not taking calcium prior to DXA. Internists were more likely than family practitioners to recommend calcium, and their patients reported better medication adherence, as did those with osteoporosis compared with osteopenia. We conclude that, while most participants are informed of the results of their DXAs, the retained information may not be accurate. Correct understanding of DXA results may lead to higher treatment rates and better adherence to treatment among patients with low BMD.

[1]  P Tugwell,et al.  Influence of bone densitometry results on the treatment of osteoporosis. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[2]  F. Korkusuz,et al.  Burden of osteoporosis. , 2006, Clinical orthopaedics and related research.

[3]  B. Ettinger,et al.  Early discontinuation of treatment for osteoporosis. , 2003, The American journal of medicine.

[4]  P Burckhardt,et al.  [Epidemiology of osteoporosis]. , 1997, Schweizerische medizinische Wochenschrift.

[5]  E. Barrett-Connor,et al.  Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. , 2001, JAMA.

[6]  Michael C. Nevitt,et al.  Mortality Following Fractures in Older Women: The Study of Osteoporotic Fractures , 1996 .

[7]  V. Kaklamani,et al.  Assessment of physician responses to abnormal results of bone densitometry studies. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  M. Mcdermott,et al.  Lack of Diagnosis and Treatment of Osteoporosis in Men and Women After Hip Fracture , 2003, Pharmacotherapy.

[9]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[10]  H. Perry,et al.  Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. , 2000, The American journal of medicine.

[11]  G. Herrero-Beaumont,et al.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. , 2004, Clinical therapeutics.

[12]  H. Sung,et al.  The Burden of Osteoporosis in California, 1998 , 2002, Osteoporosis International.

[13]  Susan Mehle,et al.  Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. , 2002, Mayo Clinic proceedings.

[14]  J. Kanis,et al.  The burden of osteoporosis , 1999, Journal of endocrinological investigation.

[15]  P. Delmas,et al.  Treatment of postmenopausal osteoporosis , 2002, The Lancet.

[16]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[17]  M. Rodríguez-Martínez,et al.  Role of Ca2+ and vitamin D in the prevention and treatment of osteoporosis , 2002 .

[18]  B. Ettinger,et al.  Initiation of Osteoporosis Treatment after Bone Mineral Density Testing , 2001, Osteoporosis International.

[19]  D. Bonneh,et al.  Awareness of Osteoporosis and Compliance with Management Guidelines in Patients with Newly Diagnosed Low-Impact Fractures , 2001, Osteoporosis International.

[20]  D. Solomon,et al.  Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. , 2000, The Journal of rheumatology.

[21]  D. Shewmon,et al.  Hip fracture patients are not treated for osteoporosis: a call to action. , 2002, Arthritis and rheumatism.

[22]  M. Rodríguez-Martínez,et al.  Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis. , 2002, Pharmacology & therapeutics.

[23]  Jacques P. Brown,et al.  Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database , 2003, Osteoporosis International.